SCIESCOPUSQ1
JTO Clinical and Research Reports
ELSEVIER, United States
JTO Clinical and Research Reports is an academic journal published by ELSEVIER (United States). Identifiers: eISSN 2666-3643. Indexed in SCIE, SCOPUS. Metrics: JIF 3.5, CiteScore 5.6, SJR 1.533, SNIP 0.89. Subject areas: RESPIRATORY SYSTEM. tlooto lists 996 papers from this journal.
CiteScore
5.60
Scopus citation metric
SJR
1.533
SCImago rank
SNIP
0.89
Source normalized impact
Percentage rank
-
JIF percentile rank
Journal profile
- ISSN
- -
- eISSN
- 2666-3643
- Abbreviation
- JTO CLIN RES REP
- Publisher
- ELSEVIER
- Country
- United States
Web of Science categories
No Web of Science category data available.
Scopus ASJC categories
2730 Oncology2740 Pulmonary and Respiratory Medicine
Papers in this journal
Recent papers
- Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis
2026
- Integration of Histologic Pattern Classifiers and Graph Convolutional Networks for Prognostic Prediction in Lung Adenocarcinoma
2026
- Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study
2026
- Oncological Outcomes of Complete Versus Limited Thymectomy in Early Stage Thymic Epithelial Tumors: A Systematic Review and Individual Patient Data Meta-Analysis
2026
- APEX: A Web-Based Tool for Assessing Long-Term Outdoor PM2.5 Exposure—Brief Report
2026 · 1 citations
Most cited papers
- Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020
2020 · 135 citations
- Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
2022 · 116 citations
- Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
2021 · 74 citations
- Implementing Lung Cancer Screening in Europe: Taking a Systems Approach
2022 · 71 citations
- EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
2020 · 71 citations